Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Moiety

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    26 result(s) found for: Moiety. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2007-003627-20 Sponsor Protocol Number: NAI008/I Start Date*: 2009-01-28
    Sponsor Name:University of Dundee, Research & Innovation Services
    Full Title: Comparative Relative Lung Bioavailability of HFA-Seretide via spacer devices in healthy volunteers
    Medical condition: Bronchial Asthma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-005565-23 Sponsor Protocol Number: CQVM149B2204 Start Date*: 2017-04-12
    Sponsor Name:Novartis Pharma AG
    Full Title: A multicenter, randomized, double-blind, placebo-controlled 3-period complete cross-over study to assess the bronchodilator effects and safety of glycopyrronium bromide (NVA237) (25 µg and 50 µg o....
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) LV (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004818-28 Sponsor Protocol Number: CNVA237A2320 Start Date*: 2015-07-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, parallel group, 26-week study evaluating the efficacy, safety and tolerability of NVA237 given once or twice daily, in patients with moderate and severe chronic obstruct...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) HU (Completed) BE (Completed) SE (Completed) GB (Completed) BG (Completed) PL (Completed) RO (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001104-36 Sponsor Protocol Number: NAI005/I Start Date*: 2006-04-27
    Sponsor Name:University of Dundee (Research & Innovation Services)
    Full Title: COMPARATIVE LUNG BIOAVAILABILITY OF HFA-SERETIDE VIA SPACER DEVICES IN HEALTHY VOLUNTEERS
    Medical condition: Bronchial Asthma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-005010-22 Sponsor Protocol Number: LY03004/CT-EUR-101 Start Date*: 2019-04-26
    Sponsor Name:Nanjing Luye Pharmaceutical Co., Ltd.
    Full Title: A Randomized, Open-Label, Cross-over Study to Assess the Relative Bioavailability of LY03004 and EU Risperdal® Consta® at 50 mg Following Multiple Intramuscular Injections in Stable Patients with S...
    Medical condition: schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HR (Completed)
    Trial results: View results
    EudraCT Number: 2021-004972-32 Sponsor Protocol Number: CQVM149C2201 Start Date*: 2022-06-23
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A Phase II, double-blind, randomized, multiple dose, cross over, three-treatment, three-period, six sequence placebo controlled trial to evaluate efficacy, pharmacokinetics (PK), pharmacodynamics (...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) HU (Trial now transitioned) PL (Trial now transitioned) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-010191-19 Sponsor Protocol Number: ALS-002-2009 Start Date*: 2010-03-19
    Sponsor Name:Alloksys Life Sciences BV
    Full Title: A randomized, double-blind, placebo-controlled phase IIIa study on bIAP, an anti-inflammatory moiety, in patients undergoing combined aortic valve replacement and coronary artery bypass grafting.
    Medical condition: Patients undergoing invasive cardiac surgery with prolonged perfusion time. This often is associated with potentially life-threatening inflammatory complications due to ischemic periods during surg...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10057944 Combined valvular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004930-41 Sponsor Protocol Number: 9766-CL-0046 Start Date*: 2020-01-22
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A Phase 1, Open-Label, Multicenter, Non-comparative Pharmacokinetics and Safety Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
    Medical condition: This is a phase I pharmacokinetic study and does not investigate a medical condition
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-001677-26 Sponsor Protocol Number: DRI4553 Start Date*: 2005-01-25
    Sponsor Name:Sanofi-Synthelabo Recherche
    Full Title: Nolpitantium Besylate In patients with mild to moderate Ulcerative Colitis: a double-blind, placebo-controlled Efficacy and safety, 8-week study.
    Medical condition: Patients with 5-aminosalicylic acid (5-ASA) or sulphasalazine resistant ulcerative colitis.
    Disease: Version SOC Term Classification Code Term Level
    7.0 10045365 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) SE (Completed) CZ (Completed) EE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002526-43 Sponsor Protocol Number: 150998-001 Start Date*: 2012-01-30
    Sponsor Name:Allergan Limited
    Full Title: Single and Repeat Dose Study of the Safety and Efficacy of AGN-150998 in Patients with Exudative Age-related Macular Degeneration
    Medical condition: Exudative Age-related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10025411 Macular degeneration senile LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019155-22 Sponsor Protocol Number: M13-385 Start Date*: 2012-05-15
    Sponsor Name:Abbott Healthcare Products B.V.
    Full Title: A Prospective, Randomized, Double-Blind, Parallel-Group Study to Compare the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Subjects with Essential Hypertension
    Medical condition: Essential Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10015488 Essential hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004472-21 Sponsor Protocol Number: PCS_03_16 Start Date*: 2017-08-31
    Sponsor Name:Pieris Pharmaceuticals GmbH
    Full Title: Phase IIa study to evaluate the safety, pharmacokinetics, and pharmacodynamics of repeated administrations over 4 weeks of the hepcidin antagonist PRS-080#022-DP in anemic chronic kidney disease pa...
    Medical condition: Anemia of chronic disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10054310 Anemia of chronic disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-016973-13 Sponsor Protocol Number: LX1606.1-203-CS Start Date*: 2010-03-08
    Sponsor Name:Lexicon Pharmaceuticals, Inc
    Full Title: A Phase 2, Open-Label, Multi-Center, Serial Ascending-Dose, Dose Finding Study to Evaluate the Safety and Tolerability of LX1606 in Subjects with Symptomatic Carcinoid Syndrome
    Medical condition: Symptomatic Carcinoid Syndrome
    Disease: Version SOC Term Classification Code Term Level
    15.1 10014698 - Endocrine disorders 10007270 Carcinoid syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-007346-63 Sponsor Protocol Number: ALS-003-2008 Start Date*: 2011-04-05
    Sponsor Name:Alloksys Life Sciences B.V.
    Full Title: Reumap: An Open Label phase II study of Bovine Intestinal Alkaline Phosphatase (bIAP), An Inflammation modulating moiety, in RA patients
    Medical condition: Rheumatoid Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2015-000535-33 Sponsor Protocol Number: BCII_2015 Start Date*: 2015-12-01
    Sponsor Name:University Medical Center Groningen
    Full Title: Phase II, Open-Label Study to Evaluate Safety and Explore Efficacy of Escalating Doses of Bevacizumab-IRDye800CW as an Optical Imaging Agent to Detect Cancer Tissue Delineation During Tumor Resecti...
    Medical condition: Patients with breast cancer eligible for surgery
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001029-30 Sponsor Protocol Number: PENTA22-Viiv212968 Start Date*: 2021-08-11
    Sponsor Name:Fondazione Penta ONLUS
    Full Title: A multicenter, open-label, single-arm trial to evaluate the safety, pharmacokinetics and antiviral activity of fostemsavir in combination with optimized background therapy (OBT) in HIV-1 infected c...
    Medical condition: HIV-1 infection in children and adolescents with Multi Drug-Resistant virus
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10020447 Human immunodeficiency virus type I infection with other conditions LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004137-18 Sponsor Protocol Number: CO-ACT-001 Start Date*: 2007-10-19
    Sponsor Name:Collaborative group for Adrenocortical Carcinoma Therapy (COAT) [...]
    1. Collaborative group for Adrenocortical Carcinoma Therapy (COAT)
    2. University of Würzburg, Internat. study-Coordinator
    Full Title: First International Randomized trial in locally advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)
    Medical condition: chemotherapy with etoposide, doxorubicin and cisplatin plus mitotane (EDP/M) as first line treatment versus streptozotocin plus mitotane (Sz/M) as first line treatment in advanced and Metastatic Ad...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10001388 Adrenocortical carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2006-001012-68 Sponsor Protocol Number: CA182-006 Start Date*: 2007-04-17
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized 2-Arm, Open Label, Phase II Study of BMS-582664, Administered Orally At A Dose of 800 mg Daily or Doxorubicin Administered Intravenously At A Dose of 60 mg/m2 Every 3 Weeks In Patients...
    Medical condition: Unresectable, advanced or metastatic hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-005106-25 Sponsor Protocol Number: D8241C00001 Start Date*: 2021-11-15
    Sponsor Name:AstraZeneca AB
    Full Title: A Modular Phase I/II, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD0466 Monotherapy or in Combination in Patients with Advanced...
    Medical condition: Advanced Haematological Malignancies
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007051 Cancer (NOS) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001619-65 Sponsor Protocol Number: TV46000-CNS-30072 Start Date*: 2018-11-14
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneou...
    Medical condition: Maintenance treatment of schizophrenia in patients currently treated with oral antipsychotics
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 20 10:58:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA